Randomized Trials Stopped Early for Harm in HIV/AIDS: A Systematic Survey
- 2 February 2006
- journal article
- review article
- Published by Informa UK Limited in HIV Research & Clinical Practice
- Vol. 7 (1), 24-33
- https://doi.org/10.1310/feed-6t8u-0bug-6hqh
Abstract
Purpose: The decision to stop trials early because of the harmful effects of the intervention is complex and requires weighing statistical, logistical, and ethical considerations. We assessed the prevalence of randomized clinical trials (RCTs) stopped early for harm in HIV/AIDS and determined the quality of reporting of methods to inform the decision to stop the trial. Method: We searched 11 electronic databases and major conference abstract databases, contacted trialist and advocacy groups, and searched the Internet. We selected RCTs stopped early for harm. We extracted data on journal and year of publication, reporting of methods and funding, planned sample size, number and planning of interim analyses, stopping rules, and effect size of the harm outcomes. Results: We found 10 RCTs stopped early for harm (median, n = 85; range, 7-1227). Most interventions (n = 9) were antiviral drugs; one trial studied vitamins to prevent vertical transmission of HIV. Five studies reported a priori defined adverse events, and only 1 trial reported planned stopping guidelines. The primary harm outcomes reported across trials included toxicity, death, and increased mother-to-child transmission. Two trials were stopped due to sudden unanticipated adverse events (Stevens-Johnson syndrome, death, and encephalopathy). Relative risk point estimates for harm ranged from 1 to 6.18. Six studies reported the presence of a data safety and monitoring board. Conclusion: The reporting of methods to inform the decision to stop trials for harm in this population is deficient in a variety of ways, including lack of stopping guidelines. Clinicians should interpret RCTs stopped early for harm with caution and interpret the results in light of related evidence. Trialists should improve the transparency of their decision-making regarding early stopping for harmful effects.Keywords
This publication has 33 references indexed in Scilit:
- Clinical Trials Results Databases: Unanswered QuestionsScience, 2006
- The quality of randomized trial reporting in leading medical journals since the revised CONSORT statementContemporary Clinical Trials, 2005
- Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trialsBMJ, 2005
- Quadruple-Drug Induction HAART in Advanced HIV InfectionHIV Research & Clinical Practice, 2005
- Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trialAIDS, 2003
- Long‐Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and on Immunologic and Virologic ParametersThe Journal of Infectious Diseases, 2003
- Immunological and Virological Changes in Antiretroviral Naive Human Immunodeficiency Virus Infected Patients Randomized to G-CSF or Placebo Simultaneously with Initiation of HAARTScandinavian Journal of Immunology, 2000
- Prospective Randomized Trial of Four Three‐Drug Regimens in the Treatment of DisseminatedMycobacterium aviumComplex Disease in AIDS Patients: Excess Mortality Associated with High‐Dose ClarithromycinClinical Infectious Diseases, 1999
- Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitisThe Lancet, 1992
- Statistical Problems in the Reporting of Clinical TrialsNew England Journal of Medicine, 1987